Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability
Janssen Has First Combo Data, With Its Own Darzalex
Executive Summary
Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.
You may also be interested in...
As CAR-T Therapies Move Into Earlier Lines, Best Uses Begin To Come Into Focus
Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.
Regeneron Has Strong Showing, But No REGEN-COV Sales Expected In First Half
Dupixent sales grew by more than 50% as Eylea and REGEN-COV also drove sales growth, though the antiviral advantage will vanish due to the FDA restricting its use.
Broader Horizons For Advanced Biotech In 2022: New Targets, Settings For IO, Cell And Gene Therapy
US FDA’s user fee goal calendar for 2022 already contains 45 applications for novel agents featuring a wide array of biologics, from cell therapy in cancer and hematology to bispecifics and new immuno-oncology targets that could move the field beyond PD-1/L1.